Improved accuracy and usability for SciBase Nevisense can create a larger market
SciBase announced today that they have achieved positive and promising results in their validation testing of an improved measurement method and algorithm for melanoma detection with their product Nevisense. The changes include a streamlining of the measurement method so that is easier to learn and use. The aim of the change is a dramatic improvement in ease of use and thus make the product much easier to integrate into the patient flow at a Dermatology clinic. In addition the new algorithm provides an improved accuracy. SciBase is now working on finalizing the release plan of an updated product.
"We have communicated previously that simplifying the method is important for us to grow both user base and customer usage rates. This improvement addresses both these issues and we see the results as a very positive sign as we try to better penetrate the mainstream market. In addition we improve test accuracy and so this is a major improvement in the product," says SciBase CEO Simon Grant.
For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com
This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on May 22, 2018.
About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and now also a FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North (“SCIB”). Avanza is the certified advisor. Further information is available on www.scibase.com.
Tags: